Erythropoietin ameliorates renal interstitial fibrosis via the inhibition of fibrocyte accumulation

Geng,Xu  Chang; Hu,Zhou  Pang; Lian,Guo  Yong

doi:10.3892/mmr.2015.3157

Erythropoietin ameliorates renal interstitial fibrosis via the inhibition of fibrocyte accumulation

Authors:
- Xu Chang Geng
- Zhou Pang Hu
- Guo Yong Lian
View Affiliations

Affiliations: Department of Urology, Wuhan Central Hospital, Wuhan, Hubei 430014, P.R. China, Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: January 8, 2015 https://doi.org/10.3892/mmr.2015.3157
Pages: 3860-3865

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Erythropoietin (EPO) is a hematopoietic hormone that protects against renal interstitial fibrosis in animal models; however, the mechanism underlying the anti‑fibrotic activity of EPO has remained elusive. The present study aimed to elucidate this mechanism. Twenty‑four male C57BL6 mice were randomly divided into four groups, each comprising six mice: (i) control group (Sh); (ii) unilateral ureteral obstruction (UUO) plus vehicle group (U+V); (ⅲ) UUO plus 300 U/kg body weight recombinant human (rh)EPO (U+E1) and (ⅳ) UUO plus 1,000 U/kg body weight rhEPO (U+E2). Seven days post‑surgery, the mice were sacrificed for examination. UUO induced significant deposition of extracellular matrix, detected by picro‑sirius red staining, which was decreased following rhEPO treatment. UUO also induced deposition of collagen I and fibronectin, rhEPO treatment was able to attenuate this effect at protein and mRNA levels. Compared with the control groups, UUO resulted in the accumulation of α‑smooth muscle actin‑positive cells in the interstitium, an effect which was ameliorated by rhEPO. Furthermore, rhEPO abrogated the UUO‑induced increase in the number of bone marrow‑derived myofibroblasts. Mechanistically, it was discovered that rhEPO decreased CXC chemokine ligand 16 (CXCL16) expression at protein level. However, treatment with rhEPO did not alter the protein expression of CC chemokine ligand 21 or CXCL12. These results suggested that rhEPO decreased fibrocyte accumulation via the suppression of renal CXCL16, which resulted in the attenuation of renal fibrosis.

View Figures

View References

1	Duffield JS: Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest. 124:2299–2306. 2014. View Article : Google Scholar : PubMed/NCBI
2	Boor P and Floege J: The renal (myo-) fibroblast: a heterogeneous group of cells. Nephrol Dial Transplant. 27:3027–3036. 2012. View Article : Google Scholar : PubMed/NCBI
3	Grgic I, Duffield JS and Humphreys BD: The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr Nephrol. 27:183–193. 2012. View Article : Google Scholar
4	Bellini A and Mattoli S: The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest. 87:858–870. 2007. View Article : Google Scholar : PubMed/NCBI
5	Pilling D and Gomer RH: Differentiation of circulating monocytes into fibroblast-like cells. Methods Mol Biol. 904:191–206. 2012.PubMed/NCBI
6	Iwano M, Plieth D, Danoff TM, Xue C, Okada H and Neilson EG: Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest. 110:341–350. 2002. View Article : Google Scholar : PubMed/NCBI
7	Li J, Deane JA, Campanale NV, Bertram JF and Ricardo SD: The contribution of bone marrow-derived cells to the development of renal interstitial fibrosis. Stem Cells. 25:697–706. 2007. View Article : Google Scholar
8	Sakai N, Wada T, Yokoyama H, et al: Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl Acad Sci USA. 103:14098–14103. 2006. View Article : Google Scholar : PubMed/NCBI
9	Chen G, Lin SC, Chen J, et al: CXCL16 recruits bone marrow-derived fibroblast precursors in renal fibrosis. J Am Soc Nephrol. 22:1876–1886. 2011. View Article : Google Scholar : PubMed/NCBI
10	Reich B, Schmidbauer K, Rodriguez Gomez M, et al: Fibrocytes develop outside the kidney but contribute to renal fibrosis in a mouse model. Kidney Int. 84:78–89. 2013. View Article : Google Scholar : PubMed/NCBI
11	Yang J, Lin SC, Chen G, et al: Adiponectin promotes monocyte-to-fibroblast transition in renal fibrosis. J Am Soc Nephrol. 24:1644–1659. 2013. View Article : Google Scholar : PubMed/NCBI
12	Oba S, Suzuki E, Nishimatsu H, et al: Renoprotective effect of erythropoietin in ischemia/reperfusion injury: possible roles of the Akt/endothelial nitric oxide synthase-dependent pathway. Int J Urol. 19:248–255. 2012. View Article : Google Scholar
13	Kaynar K, Aliyazioglu R, Ersoz S, et al: Role of erythropoietin in prevention of amikacin-induced nephropathy. J Nephrol. 25:744–749. 2012. View Article : Google Scholar : PubMed/NCBI
14	Wang W and Zhang J: Protective effect of erythropoietin against aristolochic acid-induced apoptosis in renal tubular epithelial cells. Eur J Pharmacol. 588:135–140. 2008. View Article : Google Scholar : PubMed/NCBI
15	Imamura R, Isaka Y, Sandoval RM, et al: A nonerythropoietic derivative of erythropoietin inhibits tubulointerstitial fibrosis in remnant kidney. Clin Exp Nephrol. 16:852–862. 2012. View Article : Google Scholar : PubMed/NCBI
16	Chen CL, Chou KJ, Lee PT, et al: Erythropoietin suppresses epithelial to mesenchymal transition and intercepts Smad signal transduction through a MEK-dependent mechanism in pig kidney (LLC-PK1) cell lines. Exp Cell Res. 316:1109–1118. 2010. View Article : Google Scholar : PubMed/NCBI
17	Kitamura H, Isaka Y, Takabatake Y, et al: Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model. Nephrol Dial Transplant. 23:1521–1528. 2008. View Article : Google Scholar : PubMed/NCBI
18	Park SH, Choi MJ, Song IK, et al: Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition. J Am Soc Nephrol. 18:1497–1507. 2007. View Article : Google Scholar : PubMed/NCBI
19	Chevalier RL, Forbes MS and Thornhill BA: Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int. 75:1145–1152. 2009. View Article : Google Scholar : PubMed/NCBI
20	Grande MT, Fuentes-Calvo I, Arévalo M, et al: Deletion of H-Ras decreases renal fibrosis and myofibroblast activation following ureteral obstruction in mice. Kidney Int. 77:509–518. 2010. View Article : Google Scholar
21	Kim DH, Moon SO, Jung YJ, et al: Mast cells decrease renal fibrosis in unilateral ureteral obstruction. Kidney Int. 75:1031–1038. 2009. View Article : Google Scholar : PubMed/NCBI
22	Li L, Huang L, Sung SS, et al: The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int. 74:1526–1537. 2008. View Article : Google Scholar : PubMed/NCBI
23	Formentini I, Bobadilla M, Haefliger C, et al: Current drug development challenges in chronic kidney disease (CKD) - identification of individualized determinants of renal progression and premature cardiovascular disease (CVD). Nephrol Dial Transplant. 27(Suppl 3): iii81–iii88. 2012. View Article : Google Scholar
24	Strutz F and Zeisberg M: Renal fibroblasts and myofibroblasts in chronic kidney disease. J Am Soc Nephrol. 17:2992–2998. 2006. View Article : Google Scholar : PubMed/NCBI
25	Meran S and Steadman R: Fibroblasts and myofibroblasts in renal fibrosis. Int J Exp Pathol. 92:158–167. 2011. View Article : Google Scholar : PubMed/NCBI
26	Kriz W, Kaissling B and Le Hir M: Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J Clin Invest. 121:468–474. 2011. View Article : Google Scholar : PubMed/NCBI
27	Broekema M, Harmsen MC, van Luyn MJ, et al: Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats. J Am Soc Nephrol. 18:165–175. 2007. View Article : Google Scholar
28	Niedermeier M, Reich B, Rodriguez Gomez M, et al: CD4+ T cells control the differentiation of Gr1+ monocytes into fibrocytes. Proc Natl Acad Sci USA. 106:17892–17897. 2009. View Article : Google Scholar : PubMed/NCBI
29	Bucala R, Spiegel LA, Chesney J, Hogan M and Cerami A: Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1:71–81. 1994.PubMed/NCBI
30	Wada T, Sakai N, Matsushima K and Kaneko S: Fibrocytes: a new insight into kidney fibrosis. Kidney Int. 72:269–273. 2007. View Article : Google Scholar : PubMed/NCBI
31	Chung AC and Lan HY: Chemokines in renal injury. J Am Soc Nephrol. 22:802–809. 2011. View Article : Google Scholar : PubMed/NCBI
32	Phillips RJ, Burdick MD, Hong K, et al: Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 114:438–446. 2004. View Article : Google Scholar : PubMed/NCBI
33	Boor P, Ostendorf T and Floege J: Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol. 6:643–656. 2010. View Article : Google Scholar : PubMed/NCBI